Drug Target for Cancer: CD86

Drug Targets for Cancer: CD86 and Cancer

Cluster of Differentiation 86 (CD86, also known as B7-2) residing on antigen-presenting cells is a co-stimulatory molecule. It is important for autoimmunity, transplantation, and cancer immunity. Variation of CD86 may make the immune cells dysfunctional and cause subsequent systemic inflammatory responses. CD86 functions as a key mediator of the activation of T cell in immune response. Lack of CD86 could lead to T cell inactivation and nonresponse to tumor cells, and thereby allows malignant progression of cancer.

Drug Targets for Cancer: CD86 related Products

Other vital drug targets for cancer like CD86:

Drug Targets for Cancer: CD86 Related Reference

Geng P, Zhao X, Xiang L, et al. Distinct Role of CD86 Polymorphisms (rs1129055, rs17281995) in Risk of Cancer: Evidence from a Meta-Analysis. Coleman WB, ed. PLoS ONE. 2014;9(11):e109131.

Drug Targets for Cancer: CD86 Related Information